General
The Amsterdam Cohort Hub (ACH) is dedicated to improve the infrastructure for longitudinal cohort studies in the Amsterdam region and to increase the impact of these studies in order to benefit the health of the population and society at large.
Every four weeks, ACH organizes a webinar to present our cohort-studies and discuss themes relevant for cohort studies, their staff and researchers. In January, we have scheduled the following webinar:
Thursday February 13, 16:00 – 16:45
The RODAM Study: Advancing Migrant Health in Europe, by Felix Chilunga (Amsterdam UMC)
- Overweight and COVID-19: results of the NCC collaboration, by Jolanda Boer (RIVM)
The RODAM Study: Advancing Migrant Health in Europe, by Felix Chilunga
Migrants in Europe face significant health disparities, especially in non-communicable diseases. This talk highlights findings from the RODAM study, which investigates the social and biological factors underpinning these inequalities. By uncovering key drivers, the study provides valuable insights and lays the foundation for targeted solutions to improve health outcomes for migrant communities.
Overweight and COVID-19: results of the NCC collaboration, by Jolanda Boer
Nine prospective population-based cohorts of the Netherlands Cohorts Consortium worked together to investigate the association between the degree and duration of overweight and obesity and SARS-CoV-2 infection.
Each cohort analyzed their own data using a standardized protocol and RIVM meta-analyzed the findings. Jolanda Boer will tell more about the process and results of this collaborative endeavor.
To register, please email: cohorthub@amsterdamumc.nl
Amsterdam Cohort Hub (ACH) is an initiative of Amsterdam UMC and Amsterdam Public Health research institute, in close collaboration with VU Amsterdam and UvA. For more information about ACH, please email cohorthub@amsterdamumc.nl. Your question will always be answered!
More information about ACH and affiliated cohort studies can also be found on Amsterdam Cohort Hub (amsterdamumc.org) and on our LinkedIn page.